Moderna’s mRNA-1273 Meets its Primary Endpoint in P-II/III TeenCOVE Study to Prevent COVID 19 in Adolescents

 Moderna’s mRNA-1273 Meets its Primary Endpoint in P-II/III TeenCOVE Study to Prevent COVID 19 in Adolescents

Moderna’s mRNA-1273 Meets its Primary Endpoint in P-II/III TeenCOVE Study to Prevent COVID 19 in Adolescents

Shots:

  • The P-II/III TeenCOVE study involves assessing mRNA-1273 (two 100 µg doses) vs PBO in 3700+ participants in a ratio (2:1) aged 12 to <18yrs. in the US
  • The study met its 1EPs i.e non-inferior immunogenicity and demonstrated 93% efficacy in seronegative participants after 14 days following the first dose, was generally well tolerated with a safety and tolerability profile generally consistent with the P-III COVE study in adults
  • Additionally, no cases of COVID-19 were seen in participants who had received both doses, consistent with a vaccine efficacy of 100%. The data will be submitted to regulators globally in early Jun’2021

Click here to­ read full press release/ article | Ref: Moderna | Image: STAT News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post